Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Exploring Novel Adverse Events of Nefecon - Kidney International Reports
Nefecon in IgA Nephropathy, the Nefigard trial — NephJC
FDA Approves Everest's Nefecon for IgA Nephropathy Treatment
Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from ...
(PDF) Cost-Effectiveness Analysis of Nefecon versus Best Supportive ...
WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT ...
Summary of Nefecon Benefits (Over a Lifetime Horizon) | Download ...
Cost-effectiveness analysis - Nefecon v best supportive care | CEOR
WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH ...
Asahi Kasei’s Nefecon Included in KDIGO 2025 Guideline for IgA ...
Asahi Kasei's Nefecon included in new clinical guideline | Asahi Kasei ...
Nefecon Receives Approval in China Offering New Hope to IgA Nephropathy ...
Nefecon in IgA nephropathy: real-world renal efficacy, safety profile ...
Nefecon III期临床研究完整结果公布啦！治疗IgA肾病获益结果一览 来源：肾医线近日，第60届欧洲肾脏协会（ERA）年会在意大利米兰 ...
WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR ...
Full article: Nefecon (Targeted-Release Formulation-Budesonide) for the ...
Taiwan Grants Full Approval for NEFECON IgAN Treatment
eGFR slope modelling predicts long-term clinical benefit with nefecon ...
WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF ...
Nefecon (Budesonide) - IgAN | HongKong DengYue Medicine
Everest regulatory updates in Taiwan, South Korea for Nefecon
Nefecon for treating patients with immunoglobulin A nephropathy
Nefecon filed with EMA for primary IgA Nephropathy - Calliditas ...
Everest Medicines receives full approval of NEFECON in Taiwan for ...
Calliditas’ NefIgArd study of Nefecon meets primary endpoint
Nefecon approved for use in China - Chinadaily.com.cn
Calliditas’s NefIgArd trial of Nefecon meets primary endpoint
Frontiers | Efficacy and safety of Nefecon in IgA nephropathy: real ...
Everest's kidney disease drug Nefecon gets review in Singapore ...
Calliditas enrols first patient in Phase lll study of Nefecon
NEFECON receives Chinese approval for expanded IgA nephropathy ...
South Korea approves Everest Medicines' NEFECON for treatment of ...
IgA肾病(IgAN)疗法！美国FDA授予Nefecon(定点靶向释放布地奈德)优先审查：具有疾病修正潜力! - FDA信息专区 - 生物谷
Nefecon（耐赋康，布地奈德迟释胶囊）Kinpeygo | 博鳌乐城国际药械
Breaking new ground with a late-phase rare-disease pipeline
Nefecon’s as a locally acting oral corticosteroid | DDDT
Targeted-release budesonide modifies key pathogenic biomarkers in ...
ERA 2023｜Nefecon III期临床研究完整结果公布啦！治疗IgA肾病获益结果一览_腾讯新闻
最新综述 | 一文读懂Nefecon如何对因治疗IgA肾病，显著降低蛋白尿，延缓疾病进展_腾讯新闻
10亿美元：旭化成拟收购Calliditas，云顶新耀拥有其核心管线Nefecon大中华区权益 Armstrong 2024年5月28日，日本 ...
Insights on Nefecon®, a Targeted-Release Formulation of Budesonide and ...
(PDF) Insights on Nefecon, a Targeted-Release Formulation of Budesonide ...
Full article: Insights on Nefecon®, a Targeted-Release Formulation of ...
미국 FDA, Nefecon(부데소나이드 표적 출시) 결정 날짜 연기 - 업계 뉴스 - 뉴스 - Hefei Home ...
【布地奈德,布地奈德肠溶胶囊,耐赋康,budesonide,Tarpeyo,Nefecon,Kinpeygo（欧版）】说明书_代购价格_印度 ...
Nefecon-Nefecon中文说明书,价格,哪里有卖-香港济民药业
Expected and verified benefits from old and new corticosteroid ...
Results from part A of the multi-center, double-blind, randomized ...
PHARMACOSERÍAS Marketing Farmacéutico/Pharmaceutical Marketing: Trece ...
2023年第17届东京IgA肾病国际研讨会热点速递__凤凰网
ASN 2023重磅速递 | Nefecon治疗显著延迟IgA肾病患者进展至肾衰竭的时间达12.8年_腾讯新闻
别再弄错！不是所有“布地奈德”都能治IgA肾病 - 知乎
iga肾病靶向药耐赋康Nefecon已上市进医保了！与Budenofalk、Entocort、Cortiment有何异同？ - 知乎
迄今为止，全球首个IgA肾病对因治疗药物Nefecon® III期研究重磅发表于《柳叶刀》杂志！ - 知乎
Everest Medicines Announces Acceptance of Nefecon® New Drug ...
Nefecon（耐赋康）三期临床试验显示：无论亚洲人或白种人，Nefecon均有效且耐受性良好！∣IIGANN2023 - 知乎
ASN 2023：耐赋康（Nefecon）持续降低蛋白尿，且显著延缓eGFR下降！（NefIgArd研究）-MedSci.cn
肾医线-首页
A disease-modifying approach to the treatment of IgA nephropathy ...
[데일리팜] 식약처 GIFT 2호 \'네페콘\' 허가...신규 적응증 개발
I-Mab shares rise 1.10% premarket after Everest Medicines presents real ...
云顶新耀 IgA 肾病药物——布地奈德迟释胶囊（Nefecon）拟纳入优先审评 - 知乎
全球首款IgA 肾病治疗药物！云顶新耀与 Calliditas共同开发的Nefecon的3期研究取得积极顶线结果_腾讯新闻
